Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company SignalRx Pharmaceuticals Inc.
DescriptionVascular targeted small molecule conjugate that converts to LY294002, a dual inhibitor of PI3K and mTOR
Molecular Target Phosphoinositide 3-kinase (PI3K) ; Mammalian target of rapamycin (mTOR) (FRAP) (RAFT1)
Mechanism of ActionPhosphoinositide 3-kinase (PI3K) inhibitor
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today